Quarterly ResultAug 6, 2026, 06:12 AM
Generate Biomedicines Q2: Pipeline Progress, Net Loss $67.3M
AI Summary
Generate Biomedicines reported its second quarter 2026 financial results, with a net loss of $67.3 million and revenue of $6.3 million, both showing a decline compared to the prior year. Despite the financial results, the company highlighted significant pipeline progress, including the advancement of GB-0895 Phase 3 studies in severe asthma and the enrollment of the first cohort in the GB-4362 Phase 1 study. Additionally, a biologic designed with Generate's platform was advanced into Novartis's preclinical pipeline, validating the company's generative biology platform.
Key Highlights
- GB-0895 Phase 3 studies in severe asthma advancing with global recruitment.
- GB-0895 Phase 1b data in COPD to be presented at ERS Congress on Sept. 8.
- First cohort of GB-4362 Phase 1 study enrolled for MMAE neutralizer.
- Novartis advanced a biologic designed with Generate's platform into preclinical pipeline.
- Cash, cash equivalents, and marketable securities were $457.4 million as of June 30, 2026.
- Q2 2026 revenue was $6.3 million, down from $10.1 million in Q2 2025.
- Q2 2026 net loss was $67.3 million, compared to $56.7 million in Q2 2025.
- Existing cash expected to fund operations into the first half of 2028.
Price Impact
More from GENB